Synergy Pharmaceuticals Inc (SGYP.O)
24 Mar 2017
Wed, Mar 1 2017
* Synergy Pharmaceuticals reports fourth quarter and full year 2016 financial results and business update
* Pivotal phase 3 data results for Trulance(Tm) (plecanatide) in the treatment of chronic idiopathic constipation (CIC) published in American Journal Of Gastroenterology
(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America)
Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC).
BRIEF-Synergy Pharma's Trulance receives FDA approval for treatment of adults with chronic idiopathic constipation
* Synergy Pharmaceuticals' Trulance(TM) (Plecanatide) receives U.S. FDA approval for the treatment of adults with chronic idiopathic constipation
Jan 19 The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation (CIC). (http://bit.ly/2k5wNlA)
* FDA- Trulance is manufactured by New York, New York-based Synergy Pharmaceuticals Inc Source text for Eikon: Further company coverage:
Synergy Pharmaceuticals Inc said its experimental once-daily tablet, plecanatide, met the main goal of a late-stage study on irritable bowel syndrome patients with constipation (IBS-C), according to an analysis of preliminary data.
* Synergy Pharma-co entered privately-negotiated exchange agreements with certain holders of co's 7.50% convertible senior notes due 2019
* Synergy Pharmaceuticals reports third quarter 2016 financial results and business update Source text for Eikon: Further company coverage:
- Marketplace Roundtable: Biotech Hanging In The Balance
- Synergy Pharmaceuticals (SGYP) Presents At Oppenheimer 27th Annual Healthcare Conference
- 2 Small Biotechs Under $10 To Buy Now
- Synergy's Trulance Looking Like The Next Uceris
- Biotech Forum Daily Digest: Biotech Closes Above Resistance Levels. Icahn Getting Interested In Sector?
- Biotech Forum Daily Digest: Upward Resistance Levels Continue To Hold; Spotlight On Foamix Pharmaceuticals